Clinical Drug Investigation

, Volume 17, Issue 3, pp 225–231 | Cite as

Pharmacokinetics of Fosinopril and Hydrochlorothiazide in Healthy Elderly and Young Men

  • David R. Much
  • Howard D. Uderman
  • Barbara Ameer
  • John Brennan
  • Bruce C. Stouffer
  • Daisy Whigan
  • Arthur De Vault
  • Donald VanHarken


Objective: This study evaluated the effect of advanced age on the single-dose and steady-state pharmacokinetics of the angiotensin converting enzyme inhibitor fosinopril along with the diuretic hydrochlorothiazide.

Design and Setting: Open-label, multiple-dose study in a hospital-based clinical study unit.

Study Participants: Twelve young (21 to 30 years) and 12 elderly (66 to 75 years) healthy men.

Interventions: Participants received a combination tablet of fosinopril 20mg and hydrochlorothiazide (HCTZ) 12.5mg as a single daily dose for a total of 6 doses. Drug concentrations were measured on days 1 and 7 by radioimmunoassay (fosinoprilat, the active diacid) and by HPLC (HCTZ) for calculation of first-dose and steady-state pharmacokinetic parameters.

Results: Fosinoprilat steady-state maximum serum concentration (Cmax) was somewhat higher in the elderly, but area under the serum concentration-time curve (AUC) and other pharmacokinetic parameters were similar in the young and elderly adults. As expected with age-related diminished renal function, HCTZ clearance was lower in the elderly, while its cumulative urinary excretion was similar in the two groups.

Conclusion: Advanced age is not accompanied by a clinically meaningful change in the pharmacokinetic profiles of fosinopril and HCTZ and does not warrant dose adjustment based on advanced age alone. The favourable pharmacokinetic feature of fosinopril of having dual (renal and hepatic) and compensatory elimination pathways is preserved in the elderly during combination therapy with HCTZ.


Adis International Limited Hydrochlorothiazide HCTZ Fosinopril Clin Drug Invest 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Beevers DG. Introduction: control of blood pressure by combination therapies. J Hum Hypertens 1991; 5Suppl. 2: 1–2PubMedGoogle Scholar
  2. 2.
    Kaplan NM. Introduction. Drug Invest 1991; 3Suppl. 4: 1–2Google Scholar
  3. 3.
    Kaplan NM. Combination therapy for systemic hypertension. Am J Cardiol 1995; 76: 595–7PubMedCrossRefGoogle Scholar
  4. 4.
    Chalmers J. The place of combination therapy in the treatment of hypertension in 1993. Clin Exp Hypertens 1993; 15: 1299–313PubMedCrossRefGoogle Scholar
  5. 5.
    Pool JL, Cushman WC, Saini RK, et al. Use of the factorial design and quadratic response surface models to evaluate the fosinopril and hydrochlorothiazide combination therapy in hypertension. Am J Hypertension 1997; 10: 117–23CrossRefGoogle Scholar
  6. 6.
    Weinberger MH. Influence of an angiotensin converting-enzyme inhibitor on diuretic-induced metabolic effects in hypertension. Hypertension 1983; 5Suppl. III: 132–8Google Scholar
  7. 7.
    Fillastre J-P, Hermant S, Huynen P, et al. Efficacy and tolerability of fosinopril 10mg and hydrochlorothiazide 12.5mg combination in elderly patients with hypertension: a French multicentre study. Clin Drug Invest 1997; 13: 299–307CrossRefGoogle Scholar
  8. 8.
    Duchin KL. Clinical pharmacology of fosinopril. Drug Invest 1991; 3:Suppl. 14: 12–7Google Scholar
  9. 9.
    Shionoiri H, Naruse M, Minamisawa K, et al. Fosinopril -clinical pharmacokinetics and clinical potential. Clin Pharmacokinet 1997; 32: 460–80PubMedCrossRefGoogle Scholar
  10. 10.
    UdermanHD, Much DR, Brennan J, et al. Fosinopril and hydrochlorothiazide combination versus individual components: Lack of a pharmacokinetic interaction. Ann Pharmacother. In pressGoogle Scholar
  11. 11.
    Tu J-I, Brennan J, Stouffer B, et al. Aradioimmunoassay for SQ 27,519, the active phosphinic acid-carboxylic diacid of the prodrug fosinopril in human serum. Ther Drug Monit 1990; 12: 404–12PubMedCrossRefGoogle Scholar
  12. 12.
    Cockcroft DW, Gault NH. Prediction of creatinine clearance from plasma creatinine. Br J Clin Pharmacol 1976; 16: 31–41Google Scholar
  13. 13.
    SAS Institute Inc., SAS/Stat® User’s Guide, version 6, 4th ed. Vol. 2. Cary, NC: SAS Institute Inc., 1991: 941-5Google Scholar
  14. 14.
    Chow S-C, Liu J-P. Design and analysis of bioavailability and bioequivalence studies. New York: Marcel Dekker, 1992Google Scholar
  15. 15.
    Littell RC, Freund RJ, Spector PC. SAS® System for Linear Models. 3rd ed. Cary, NC: SAS Institute Inc., 1991Google Scholar
  16. 16.
    Levinson B, Sugarman AA, Couchman T, et al. Advanced age per se has no influence on the kinetics of the active diacid of fosinopril. J Clin Pharmacol 1986; 26: 541–60Google Scholar
  17. 17.
    Hockings N, Ajayi AA, Reid JL. Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat. Br J Clin Pharmacol 1986; 21: 341–8PubMedCrossRefGoogle Scholar
  18. 18.
    Cirillo VJ, Till AE, Gomez HJ, et al. Effect of age on lisinopril pharmacokinetics [abstract]. Clin Pharmacol Ther 1986; 39: 187Google Scholar
  19. 19.
    Macdonald NJ, Elliott HL, Howie CA, et al. Age and the pharmacodynamics and pharmacokinetics of benazepril [abstract]. Br J Clin Pharmacol 1989; 27: 707B–8BGoogle Scholar
  20. 20.
    Rakhit A, Kochak GM, Tipnis V, et al. Pharmacokinetics of pentopril in the elderly. Br J Clin Pharmacol 1987; 24: 351–7PubMedCrossRefGoogle Scholar
  21. 21.
    Lees KR, Green ST, Reid JL. Influence of age on the pharmacokineticand pharmacodynamics of perindopril. Clin Pharmacol Ther 1988; 44: 418–25PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  • David R. Much
    • 1
  • Howard D. Uderman
    • 1
  • Barbara Ameer
    • 2
  • John Brennan
    • 3
  • Bruce C. Stouffer
    • 1
  • Daisy Whigan
    • 1
  • Arthur De Vault
    • 4
  • Donald VanHarken
    • 5
  1. 1.Clinical PharmacologyBristol-Myers Squibb Pharmaceutical Research InstitutePrincetonUSA
  2. 2.Consultant to Bristol-Myers Squibb Pharmaceutical Research InstitutePrincetonUSA
  3. 3.MariettaUSA
  4. 4.South San FranciscoUSA
  5. 5.Retired from Bristol-Myers Squibb Pharmaceutical Research InstitutePrincetonUSA

Personalised recommendations